By Sabela Ojea


Verona Pharma said the Food and Drug Administration approved ohtuvayre as a maintenance treatment for adults with chronic obstructive pulmonary disease.

The clinical-stage biopharmaceutical company on Wednesday said it plans to launch the treatment in the third quarter through an exclusive network of accredited specialty pharmacies.

This is the first inhaled product with a novel mechanism of action available for the maintenance treatment of chronic obstructive pulmonary in more than 20 years, Verona Pharma added.


Write to Sabela Ojea at sabela.ojea@wsj.com


(END) Dow Jones Newswires

06-26-24 1824ET